10 Jul 2023 Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure Member news
30 Jun 2023 argenx and Zai Lab announce approval of VYVGART® (efgartigimod alfa injection) for generalized myasthenia gravis in China Member news
21 Jun 2023 argenx announces U.S. Food and Drug Administration approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection for subcutaneous use in generalized myasthenia gravis Member news
12 Jun 2023 Oxurion finalizes enrollment in KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema Member news
11 May 2023 Mithra announces completion of recruitment in pediatric study of Estelle in adolescent patients Member news
04 May 2023 Member spotlight: CoMoveIT, patient-driven mobility solutions for people with complex movement disorders Multiple categories
03 Apr 2023 Sequana Medical announces submission of Investigational New Drug (IND) application for DSR® 2.0 for treatment of congestive heart failure Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
